Due to the participation of the ACE2 receptor in COVID–19 pathophysiology, it might be useful to utilise ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), which was confirmed by studies linking their administration to disease mitigation and a lower risk of all–cause mortality, especially if the patient had coexisting hypertension. This evidence concerns the gene ACE and COVID-19.